Xenon Pharmaceuticals XENE Lease Payments
Lease Payments at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeasePayments.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's lease payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's lease payments?
- Xenon Pharmaceuticals (XENE) reported lease payments of $439K in Q1 2026.
- How has Xenon Pharmaceuticals's lease payments changed year-over-year?
- Xenon Pharmaceuticals's lease payments increased by 4.5% year-over-year, from $420K to $439K.
- What is the long-term trend for Xenon Pharmaceuticals's lease payments?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's lease payments has grown at a 20.1% compound annual growth rate (CAGR), from $824K to $1.71M.
- What does lease payments mean?
- This metric measures the actual cash outflows made by the company to satisfy its obligations under operating lease agreements for facilities, equipment, or other assets. It represents a recurring fixed cost that impacts the company's operational cash flow. Tracking this helps assess the company's ongoing commitment to lease-based infrastructure and its impact on liquidity.